Who is lobbying to shape PBM (pharmacy benefit manager) reform in Congress right now? Map the organizations for and against, the bills in play, and the lobbying money, cited to the official record.

PBM Reform Lobbying Landscape

Bills in Play (119th Congress, 2025–2026):

The most-lobbied PBM reform bills are H.R. 4317 (PBM Reform Act, 140 filings), S. 526 (Pharmacy Benefit Manager Transparency Act, 97 filings), and S. 3345 (PBM Price Transparency and Accountability Act, 71 filings). Newer antitrust-focused bills include H.R. 8779 and S. 4509 (both titled "PBM Act," introduced May 2026). All are currently referred to committee.

Top Lobbying Organizations (2025–2026):

Pharmaceutical manufacturers dominate: Pharmaceutical Research and Manufacturers of America (PhRMA) leads with 62 filings; Novartis (33 filings), Novo Nordisk (21 filings), and Bristol-Myers Squibb (14 filings) follow. PBM operators themselves are active: Pharmaceutical Care Management Association (PCMA) filed 23 times; Prime Therapeutics (18 filings); CVS Health (15 filings via outside firms); Cigna (14 filings via outside firms); UnitedHealth Group (14 filings via outside firms). Pharmacy groups include National Association of Chain Drug Stores (21 filings), Independent Pharmacy Cooperative (12 filings), and National Community Pharmacists Association (2 filings on S. 526 alone).

Lobbying Spending (disclosed Senate LDA filings, 2025–2026):

On H.R. 4317: PhRMA reported $7,360,000 in expenses; PCMA $6,579,684; Amgen $2,580,000. On S. 526: Biotechnology Innovation Organization $4,920,000; Cigna $3,490,000; PCMA $3,296,694. Total PBM-related filings across all bills: 1,684 filings from 265 unique clients, 245 registrants (2025–2026).

Top Lobbying Firms: Williams and Jensen (73 filings, 12 clients), Todd Strategy Group (51 filings, 14 clients), Forbes-Tate (49 filings, 7 clients).

Note on positions: Senate LDA filings do not disclose whether filers support or oppose bills—only that they lobbied on them. The data shows activity intensity, not alignment.

Sources

• H.R. 4317 (PBM Reform Act of 2025)
• S. 526 (Pharmacy Benefit Manager Transparency Act of 2025)
• S. 3345 (PBM Price Transparency and Accountability Act)
• H.R. 8779 (PBM Act)
• S. 4509 (PBM Act)